Acadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating OverviewBusiness Wire • 08/06/25
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth ConferenceBusiness Wire • 08/05/25
Acadia Pharmaceuticals Appoints Scott Cenci as Chief Information and Data OfficerBusiness Wire • 08/04/25
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 6, 2025Business Wire • 07/23/25
Acadia Emerges From Behind The Scenes With A Potential $12 Billion OpportunityInvestors Business Daily • 07/10/25
Acadia Pharmaceuticals Hosts Inaugural R&D Day Showcasing Pipeline and Long-Term Value DriversBusiness Wire • 06/25/25
U.S. Court of Appeals for the Federal Circuit Affirms Prior Delaware District Court Rulings in Favor of Acadia in NUPLAZID® (pimavanserin) Composition of Matter PatentBusiness Wire • 06/09/25
Acadia Pharmaceuticals to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness Wire • 05/29/25
Acadia Pharmaceuticals Appoints Allyson McMillan-Youngblood as Senior Vice President, Rare Disease FranchiseBusiness Wire • 05/27/25
ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid PatentZacks Investment Research • 05/19/25
Delaware District Court Rules in Favor of Acadia in NUPLAZID® (pimavanserin) Formulation Patent LitigationBusiness Wire • 05/16/25
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue Estimates (Revised)Zacks Investment Research • 05/09/25
Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue GrowthZacks Investment Research • 05/08/25
ACADIA Pharmaceuticals Inc. (ACAD) Q1 2025 Earnings Conference Call TranscriptSeeking Alpha • 05/08/25
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings and Revenue EstimatesZacks Investment Research • 05/07/25